DBVT Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals Plc has a net margin of -- compared to DBV Technologies SA's net margin of --. DBV Technologies SA's return on equity of -217.87% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

DBV Technologies SA has a consensus price target of $39.89, signalling upside risk potential of 89.39%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $7.02 which suggests that it could grow by 704.13%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than DBV Technologies SA, analysts believe Biodexa Pharmaceuticals Plc is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.942, which suggesting that the stock is 194.186% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.106, suggesting its more volatile than the S&P 500 by 10.59%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. DBV Technologies SA's net income of -$44.8M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -- compared to DBV Technologies SA's net margin of -253.13%. DBV Technologies SA's return on equity of -217.87% beat Cellectis SA's return on equity of -65.19%.

DBV Technologies SA has a consensus price target of $39.89, signalling upside risk potential of 89.39%. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 112.61%. Given that Cellectis SA has higher upside potential than DBV Technologies SA, analysts believe Cellectis SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.942, which suggesting that the stock is 194.186% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.907, suggesting its more volatile than the S&P 500 by 190.653%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.4M. DBV Technologies SA's net income of -$44.8M is lower than Cellectis SA's net income of -$26.3M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 4.85x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

EDAP TMS SA has a net margin of -- compared to DBV Technologies SA's net margin of -43.22%. DBV Technologies SA's return on equity of -217.87% beat EDAP TMS SA's return on equity of -91.49%.

DBV Technologies SA has a consensus price target of $39.89, signalling upside risk potential of 89.39%. On the other hand EDAP TMS SA has an analysts' consensus of $6.83 which suggests that it could grow by 101.57%. Given that EDAP TMS SA has higher upside potential than DBV Technologies SA, analysts believe EDAP TMS SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.942, which suggesting that the stock is 194.186% less volatile than S&P 500. In comparison EDAP TMS SA has a beta of -0.085, suggesting its less volatile than the S&P 500 by 108.542%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EDAP TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. EDAP TMS SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than EDAP TMS SA quarterly revenues of $21.9M. DBV Technologies SA's net income of -$44.8M is lower than EDAP TMS SA's net income of -$9.4M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while EDAP TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 1.72x for EDAP TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

NuCana Plc has a net margin of -- compared to DBV Technologies SA's net margin of --. DBV Technologies SA's return on equity of -217.87% beat NuCana Plc's return on equity of -215.21%.

DBV Technologies SA has a consensus price target of $39.89, signalling upside risk potential of 89.39%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 1275973.62%. Given that NuCana Plc has higher upside potential than DBV Technologies SA, analysts believe NuCana Plc is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.942, which suggesting that the stock is 194.186% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.791, suggesting its more volatile than the S&P 500 by 79.145%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. DBV Technologies SA's net income of -$44.8M is lower than NuCana Plc's net income of -$3.3M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.